7BIO
(Synonyms: 7-Bromoindirubin-3’-oxime) 目录号 : GC16037A caspase-independent (nonapoptotic) cell death inducer
Cas No.:916440-85-2
Sample solution is provided at 25 µL, 10mM.
7-bromoindirubin-3'-oxime (7BIO), a derivative of indirubin, is a caspase independent nonapoptotic cell death inducer [1]. 7-bromoindirubin-3'-oxime is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
FLT3 is a cytokine receptor expressed on the surface of many hematopoietic progenitor cells. Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. DYRK1A and DYRK2 have been involved in catalyzing its autophosphorylation on serine/threonine and tyrosine residues and play a significant role in a signaling pathway regulating cell proliferation. Aurora kinases are serine/threonine kinases which are essential for cell proliferation and cellular division by controlling chromatid segregation.
7-bromoindirubin-3'-oxime (7BIO) showed a marginal inhibitory activity towards CDKs and GSK-3. 7BIO triggered a rapid cell death process distinct from apoptosis. 7BIO induced the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7BIO-induced cell death was not accompanied by cytochrome c release neither by any measurable effector caspase activation. 7BIO triggered the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. 7BIO inhibited FLT3, the dual-specificity tyrosine phosphorylation-regulated kinases, DYRK1A and DYRK2 with the IC50 values of 0.34 μM, 1.9 and 1.3 μM, respectively [2]. 7BIO also inhibited the activity of Aurora B and C kinases with IC50 values of 4.6 and 0.7 μM, respectively [3].
References:
[1] Ribas J, Bettayeb K, Ferandin Y, et al. 7-Bromoindirubin-3′-oxime induces caspase-independent cell death[J]. Oncogene, 2006, 25(47): 6304-6318.
[2] Myrianthopoulos V, Kritsanida M, Gaboriaud-Kolar N, et al. Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases[J]. ACS medicinal chemistry letters, 2012, 4(1): 22-26.
[3] Myrianthopoulos V, Magiatis P, Ferandin Y, et al. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins[J]. Journal of medicinal chemistry, 2007, 50(17): 4027-4037.
Cas No. | 916440-85-2 | SDF | |
别名 | 7-Bromoindirubin-3’-oxime | ||
化学名 | 7-bromo-3-[1,3-dihydro-3-(hydroxyimino)-2H-indol-2-ylidene]-1,3-dihydro-2H-indol-2-one | ||
Canonical SMILES | O/N=C(C1=CC=CC=C1N2)/C2=C3C(NC4=C(Br)C=CC=C4/3)=O | ||
分子式 | C16H10BrN3O2 | 分子量 | 356.2 |
溶解度 | DMSO : 250 mg/mL (701.91 mM; Need ultrasonic); Ethanol : 50 mg/mL (140.38 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.8074 mL | 14.0371 mL | 28.0741 mL |
5 mM | 0.5615 mL | 2.8074 mL | 5.6148 mL |
10 mM | 0.2807 mL | 1.4037 mL | 2.8074 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet